Propanc Biopharma, Inc. Common Stock
Here’s whether Propanc Biopharma, Inc. Common Stock (PPCB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 55 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-17.30% over 10 days); weak 1-year return of -99.4%; 3-month momentum negative (-64.4%); rising volume on a downtrend (distribution, 2.33x avg). Currently 99.4% off its 52-week high. Score: -5/7.
PPCB is trading below its 200-day MA ($1.83) — a key warning sign the longer-term trend is under pressure. An RSI of 54.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -99.4% compares to +35.1% for SPY (trailed the market by 134.5%). The current 99.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.